Nasdaq · Biotech stocks database
CNTB (Connect Biopharma Holdings Limited) stock: $0.70, $44.1M market cap, $31.5M cash, $12.6M EV, $55.1M fully diluted market cap. Lead program: Rademikibart (Asthma Acute; COPD Exacerbation Acute), Phase 2. Data from Fully Diluted's biotech stocks database.
Connect Biopharma, headquartered in San Diego, California, is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (“COPD”). The Company is advancing rademikibart, a next-generation, potentially best-in-class antibody designed to target interleukin-4-receptor alpha (“IL-4Rα”).
Source: 10-K FY2025 via SEC EDGAR
| Cash | $31.5M |
|---|---|
| Debt | $0.0M |
| Net cash | $31.5M |
| Enterprise value | $12.6M |
| Basic shares | 63.0M shares |
| Fully diluted shares | 78.8M shares |
| Fully diluted market cap | $55.1M |
| Cash per share | $0.50 |
| Quarterly burn | $15.9M |
| Cash runway | 2.0 quarters |
Cash figures as of 2026-06-30. Database snapshot: 2026-11-10.
Cap table as of 2026-06-30.
Loading CNTB daily closes…